Eden Biodesign and the University of Manchester Intellectual Property Limited Develop Innovative Treatment for Cancer
Complete the form below to unlock access to ALL audio articles.
Eden Biodesign Ltd has announced that it has been selected by UMIP to provide a range of services for the development of therapeutic for treatment of macular degeneration and cancer.
Professor Paul Bishop, School of Medicine, University of Manchester, who leads the team that discovered the new therapeutic, commented: “We are very pleased for this exiting programme to be further developed by Eden Biodesign. The experience of Eden Biodesign’s management team in the development of biologics ensures that our programme will be well positioned for an accelerated clinical development and will increase the value of our programme to industrial partners.”
“We look forward to helping UMIP and Professor Bishop to accelerate the transfer of this new therapy from research labs into clinical development”, said Dr Crawford Brown, CEO of Eden Biodesign. “Eden Biodesign has the expertise in product development and manufacturing that is critical to ensure clinical and commercial success of this product.”
Professor Paul Bishop has been awarded a grant from the National Biomanufacturing Centre (NBC) Access Fund administered by the Northwest Regional Development Agency (NWDA) towards the cost of the project.
The project will be executed at the NBC, operated by Eden Biodesign and funded by NWDA, European Regional Development Fund (ERDF) and Department of Trade and Industry.
“We are pleased that the NBC is able to provide practical help to Professor Paul Bishop and UMIP Ltd for the commercialisation of their discoveries which have the potential to offer both patient benefit and consolidation of the UK’s lead in biopharmaceutical development in Europe” said Dr Linda Magee, NWDA Biotechnology Sector Director & Head of Bionow.
Dr Rich Ferrie, Head of BioMedica Operations at UMIP added, “This is the first of a number of our projects that should benefit from the excellent facilities at NBC and the product development expertise of Eden Biodesign. We believe that Opticin has tremendous therapeutic potential and the work package planned is an important next step in our strategy of partnering this programme.”
